AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

Amgen (NASDAQ:AMGN) today announced new data at the American Diabetes Association (ADA) 86th Scientific Sessions reinforcing its commitment to addressing unmet needs for people living with ...

Is Amgen An Undervalued Stock Or Value Trap?

Amgen (AMGN) stock is at an interesting point right now. If you bet on it, you are betting on a company that's growing reasonably, is sustaining good cash flow and margin, has a low-debt to market ...

Amgen: Time For An Upgrade? Yes, I Think So

Amgen Inc. upgraded to cautious Buy: pipeline growth drivers, margin upside, and risk/reward near lows. Click for this AMGN ...
KXAN

AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S.

THOUSAND OAKS, Calif., Oct. 6, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha ® (evolocumab). This follows ...
Health Affairs

Amgen’s Retreat: Denmark, Repatha, And The Collision Course Of US MFN Pricing Policy

Repatha is not a drug where Amgen has pricing power to absorb such exposure. The Denmark exit should be read as a rational, if disruptive, response to that specific vulnerability — not as the ...
Nasdaq

Amgen's Repatha, Evenity & Blincyto Drive Sales This Earnings Season

Amgen AMGN delivered yet another strong quarterly performance. Its second-quarter 2025 earnings and sales beat estimates. The company has been recording consistently strong top-line performance. Amgen ...